NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

1903. The Medicare drug benefit coverage gap: the basics

1904. National spending for long-term services and supports (LTSS): the basics

1906. Classification of products as drugs and devices & additional product classification issues: final guidance : guidance for industry and FDA staff

1907. Advancement of emerging technology applications for pharmaceutical innovation and modernization

1908. Compliance policy for required warning statements on small-packaged cigars

1909. Center for Devices and Radiological Health appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff

1910. Developing and responding to deficiencies in accordance with the least burdensome provisions: guidance for industry and Food and Drug Administration staff

1911. Requests for feedback on medical device submissions: the pre-submission program and meetings with Food and Drug Administration staff : guidance for industry and Food and Drug Administration staff

1912. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

1913. Display devices for diagnostic radiology: guidance for industry and Food and Drug Administration staff

1914. M4 organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use

1916. Deciding when to submit a 510(k) for a change to an existing device: guidance for Industry and Food and Drug Administration staff

1917. Deciding when to submit a 510(k) for a software change to an existing device: guidance for industry and Food and Drug Administration staff

1918. De novo classification process (evaluation of automatic class III designation): guidance for industry and Food and Drug Administration staff

1919. Product labeling for certain ultrasonic surgical aspirator devices: guidance for Industry and Food and Drug Administration staff

1920. Manufacturers sharing patient-specific information from medical devices with patients upon request: guidance for industry and Food and Drug Administration staff

1921. Formal dispute resolution: sponsor appeals above the division level : guidance for industry and review staff : good review practice

1923. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment

1924. Recurrent herpes labialis: developing drugs for treatment and prevention

1925. Evaluating drug effects on the ability to operate a motor vehicle

1926. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff

1927. Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers regarding the scope of the exception

1928. Unique device identification: direct marking of devices : guidance for Industry and Food and Drug administration staff

1929. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products

1930. Pediatric information for x-ray imaging device premarket notifications: guidance for industry and Food and Drug Administration staff

1931. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry

1932. FDA categorization of investigational device exemption (IDE) devices to assist the Centers for Medicare and Medicaid Services (CMS) with coverage decisions: guidance for sponsors, clinical investigators, industry, institutional review boards, and Food and Drug Administration staff

1933. Technical considerations for additive manufactured medical devices: guidance for industry and Food and Drug Administration staff

1934. Use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components

1935. Software as a medical device (SAMD): clinical evaluation : guidance for industry and Food and Drug Administration staff

1937. Systemic antibacterial and antifungal drugs: susceptibility test interpretive criteria labeling for NDAs and ANDAs

1938. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system

1939. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

1940. Unique device identification: policy regarding compliance dates for class I and unclassified devices : immediately in effect guidance for industry and Food and Drug Administration staff

1941. Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act

1944. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

1970. Ebola

1976. [A nurse serving a hot drink in a cup]

1989. Holy Cross Central School of Nursing: a central school of nursing located in Indiana and Illinois : conducted by the Sisters of the Holy Cross and the Sisters of St. Joseph : in the heart of the Midwest close to home

1996. "Nurses"